BioCis has announced positive results from phase IIa clinical trial of ProtoCure emulsion cream, a new topical drug for dermatology. The double-blind, placebo-controlled study was conducted in Finland. It included 13 patients with mild-to-moderate atopic dermatitis, who applied the ProtoCure emulsion cream to the affected skin areas twice daily for up to four weeks. The objectives were to evaluate the tolerability, pharmacokinetics, and efficacy of the topical treatment.
According to the company, study results showed excellent safety profile, and no serious adverse events were reported during the study.
Lasse Leino, CEO of BioCis, said: We are very pleased with the promising results of this study. Skin barrier dysfunction is now recognized as a hallmark feature of atopic dermatitis. Any drug showing capacity for restoring this disturbance has significant potential in atopic dermatitis therapy. Based on our results, ProtoCure emulsion cream holds great promises in the treatment of inflammatory skin disorders.